(Q30354478)

20 June 2017

Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. (English)

1 reference

20 June 2017

3

Terrence M Tumpey

1 reference

20 June 2017

William A Ernst

1

1 reference

20 June 2017

Hyung J Kim

2

1 reference

20 June 2017

Airan D A Jansen

4

1 reference

20 June 2017

Wendy Tai

5

1 reference

20 June 2017

Donald V Cramer

6

1 reference

20 June 2017

Jill P Adler-Moore

7

1 reference

20 June 2017

Gary Fujii

8

1 reference

20 June 2017

language of work or name

English

0 references

publication date

2 May 2006

1 reference

20 June 2017

1 reference

20 June 2017

24

1 reference

20 June 2017

5158-5168

1 reference

20 June 2017

24

1 reference

Human infection with influenza H9N2.

20 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

The economic impact of pandemic influenza in the United States: priorities for intervention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

Lethal H5N1 influenza viruses escape host anti-viral cytokine responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

Preparing for the next pandemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

Antibody response to the M2 protein of influenza A virus expressed in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

A universal influenza A vaccine based on the extracellular domain of the M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

Modified M2 proteins produce heterotypic immunity against influenza A virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

A molecular model for membrane fusion based on solution studies of an amphiphilic peptide from HIV gp41

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

Defensins promote fusion and lysis of negatively charged membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

To fuse or not to fuse: the effects of electrostatic interactions, hydrophobic forces, and structural amphiphilicity on protein-mediated membrane destabilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

Preparation and use of liposomes in the treatment of microbial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

Mechanism of immunity to influenza: maternal and passive neonatal protection following immunization of adult ferrets with a live vaccinia-influenza virus haemagglutinin recombinant but not with recombinants containing other influenza virus proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Microbial adaptation and change: avian influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.04.008

1 reference

20 June 2017

1 reference